We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis (NVS) Kymriah Misses Primary Endpoint in NHL Study
Read MoreHide Full Article
Novartis (NVS - Free Report) announced that the phase III BELINDA study evaluating Kymriah (tisagenlecleucel) in second-line non-Hodgkin lymphoma (“NHL”) fails to meet its primary endpoint of event-free survival (“EFS”) compared to treatment with the standard-of-care (“SOC”).
The BELINDA study compared the efficacy, safety and tolerability between Kymriah and SOC in patients with aggressive B-cell NHL who had primary refractory disease or those who relapsed within 12 months of first-line treatment.
Shares of the company have declined 0.7% so far this year against the industry’s 19% surge.
Image Source: Zacks Investment Research
Per the study, EFS is defined as the time from the date of randomization to the date of the first documented disease progression or stable disease at or after the week 12 assessment, per blinded independent review committee, or death at any time.
Novartis will complete a full evaluation of the BELINDA study data and work alongside the study investigators for the same.
Kymriah is a CD19-directed genetically modified autologous T cell immunotherapy. It is currently approved in the United States for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse. The therapy is also approved for the treatment of elapsed or refractory adult diffuse large B-cell lymphoma (“DLBCL”). Kymriah is also the first approved CAR-T therapy.
Gilead’s (GILD - Free Report) CAR-T therapy, Yescarta, is approved for the treatment of refractory aggressive NHL, which includes DLBCL, transformed follicular lymphoma and primary mediastinal B-cell lymphoma.
Novartis currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the same sector are Horizon Therapeutics and Regeneron Pharmaceuticals (REGN - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Horizon’s earnings per share estimates for 2021 have increased from $3.62 to $4.46 in the past 30 days. The same for 2022 has risen from $5.18 to $5.84 over the same period. The stock has rallied 47.6% in the year so far.
Regeneron’s earnings per share estimates for 2021 have increased from $49.96 to $54.15 in the past 30 days. The same for 2022 has risen from $40.91 to $44.11 over the same period. The stock has rallied 38.1% in the year so far.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novartis (NVS) Kymriah Misses Primary Endpoint in NHL Study
Novartis (NVS - Free Report) announced that the phase III BELINDA study evaluating Kymriah (tisagenlecleucel) in second-line non-Hodgkin lymphoma (“NHL”) fails to meet its primary endpoint of event-free survival (“EFS”) compared to treatment with the standard-of-care (“SOC”).
The BELINDA study compared the efficacy, safety and tolerability between Kymriah and SOC in patients with aggressive B-cell NHL who had primary refractory disease or those who relapsed within 12 months of first-line treatment.
Shares of the company have declined 0.7% so far this year against the industry’s 19% surge.
Image Source: Zacks Investment Research
Per the study, EFS is defined as the time from the date of randomization to the date of the first documented disease progression or stable disease at or after the week 12 assessment, per blinded independent review committee, or death at any time.
Novartis will complete a full evaluation of the BELINDA study data and work alongside the study investigators for the same.
Kymriah is a CD19-directed genetically modified autologous T cell immunotherapy. It is currently approved in the United States for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse. The therapy is also approved for the treatment of elapsed or refractory adult diffuse large B-cell lymphoma (“DLBCL”). Kymriah is also the first approved CAR-T therapy.
Gilead’s (GILD - Free Report) CAR-T therapy, Yescarta, is approved for the treatment of refractory aggressive NHL, which includes DLBCL, transformed follicular lymphoma and primary mediastinal B-cell lymphoma.
Novartis AG Price
Novartis AG price | Novartis AG Quote
Zacks Rank & Stocks to Consider
Novartis currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the same sector are Horizon Therapeutics and Regeneron Pharmaceuticals (REGN - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Horizon’s earnings per share estimates for 2021 have increased from $3.62 to $4.46 in the past 30 days. The same for 2022 has risen from $5.18 to $5.84 over the same period. The stock has rallied 47.6% in the year so far.
Regeneron’s earnings per share estimates for 2021 have increased from $49.96 to $54.15 in the past 30 days. The same for 2022 has risen from $40.91 to $44.11 over the same period. The stock has rallied 38.1% in the year so far.